Steinberg Diagnostic Medical Imaging (SDMI) of Las Vegas has bolstered its capabilities by installing the United States’ first Celesteion PET/CT system from Toshiba America Medical Systems Inc. The Celesteion allows SDMI to provide the highest quality PET/CT (positron emission tomography/computed tomography) images and exams without sacrificing patient comfort.

The Center for Biomedical Research (CBR) is partnering with the Ackerman Cancer Center as part of a clinical meta-registry for clinical outcomes and long-term follow-up of cancer patients receiving proton therapy.

The Mevion S250 proton therapy system at Robert Wood Johnson University Hospital (RWJUH) is now treating patients, less than four weeks after the first Mevion patient was treated at Ackerman Cancer Center. The occasion marks the first time a proton manufacturer has simultaneously brought up two distinct facilities.

At Health Datapalooza, the Acting Centers for Medicare & Medicaid Services (CMS) Administrator Andy Slavitt announced a new policy that will allow innovators and entrepreneurs to access CMS data, such as Medicare claims. Under the policy, those interested may conduct approved research that will ultimately improve care and provide better tools that should benefit healthcare consumers through a greater understanding of what the data says works best in healthcare. The data will not allow the patient’s identity to be determined, but will provide the identity of the providers of care. CMS will begin accepting innovator research requests in September 2015.

Degeneration of the white matter of the brain may be an early marker of specific types of Alzheimer's disease (AD), including early-onset AD, according to a new study published in the journal Radiology.

For years, the radiology industry has focused on reducing, or eliminating patient exposure to radiation. Recently, the industry has shifted attention to the cumulative effect radiation exposure has over the course of a physician’s career.

Women aged 50-69 years who attend mammography screening reduce their risk of dying from breast cancer by 40 percent compared to women who are not screened, according to a major international review. The review covered the latest evidence on breast cancer screening.

ACE64 aspiration thrombectomy system

Bracco, Lumason, first U.S. echocardiography procedure, Morristown

Bracco Imaging announced that the first echocardiography imaging procedure with Lumason was performed in May at Morristown Medical Center, part of the Atlantic Health System, in New Jersey. This is the first administration after the development of the agent (sulfur hexafluoride lipid-type A microspheres) in the United States and approval by the U.S. Food and Drug Administration. The announcement was made through Bracco Imaging’s affiliate Bracco Diagnostics Inc.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now